Adding two classes of diabetes medications to the drug regimens of patients with type 2 diabetes and chronic kidney disease can reduce both blood glucose levels and albuminuria, a study shows.

The findings come from a double-blind placebo-controlled trial that investigated the effects of dapagliflozin (10mg/day) and saxagliptin (2.5mg/day) on patients who were also taking their usual diabetes medications and an angiotensin-converting enzyme inhibitor or an angiotensin II receptor inhibitor.